Skip to main content
COO
NASDAQ Life Sciences

Cooper Companies Reports $77.9M Net Loss in Q2 Due to $271.6M Litigation Charge

Reported by Wiseek News
Sentiment info
Negative
Importance info
8
Price
$66.9
Mkt Cap
$13.139B
52W Low
$58.89
52W High
$89.83
Market data snapshot near publication time

Summary

Cooper Companies reported a Q2 2026 net loss of $77.9 million, resulting in diluted EPS of ($0.40), despite revenue growing 7.9% to $1.08 billion. This net loss is primarily attributed to a $271.6 million litigation accrual within its CooperSurgical segment, as detailed in the recently filed 10-Q. While earlier reports focused on adjusted earnings beats, this headline highlights the GAAP loss. The substantial litigation charge significantly impacted the company's profitability, turning what would otherwise be a revenue growth story into a net loss for the quarter.

At the time of this announcement, COO was trading at $66.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1B. The 52-week trading range was $58.89 to $89.83. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

COO - Latest Insights

COO
Jun 05, 2026, 4:51 PM EDT
Source: Wiseek News
Importance Score:
8
COO
Jun 05, 2026, 4:47 PM EDT
Filing Type: 10-Q
Importance Score:
8
COO
Jun 04, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
8
COO
Jun 04, 2026, 4:16 PM EDT
Source: Reuters
Importance Score:
8
COO
May 04, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
COO
Mar 06, 2026, 4:12 PM EST
Filing Type: 10-Q
Importance Score:
8
COO
Mar 05, 2026, 4:38 PM EST
Source: Reuters
Importance Score:
8
COO
Mar 05, 2026, 4:27 PM EST
Filing Type: 8-K
Importance Score:
8
COO
Feb 24, 2026, 4:19 PM EST
Filing Type: DEF 14A
Importance Score:
8
COO
Feb 03, 2026, 9:58 PM EST
Filing Type: 8-K
Importance Score:
8